Combined Holdings of Editas Medicine (EDIT) - Updated Daily
TherapeuticsGene TherapyCAR-NK Gene TherapyCRSPR Gene Editing
Key Statistics
Statistics
| ⚖️Weighting | 🧢Market Cap |
|---|---|
| 0% | $857.33m |
| 🏋️♀️Weight Rank Across All Funds | 🌏Country |
| 343 | 🇺🇸United States |
| 💳ARK Estimated Cost Average | |
$29.86 - ARKG$29.07 - ARKK | |
| Description | |
|---|---|
| As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com. | |
| Website | |
| www.editasmedicine.com |
Research Notes and Commentary for EDIT
September 8, 2020
CRISPR Could Transform Body Fat into Energy and Weight Loss
See Section #1December 23, 2019